<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3102">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04366050</url>
  </required_header>
  <id_info>
    <org_study_id>RAMIC Trial</org_study_id>
    <nct_id>NCT04366050</nct_id>
  </id_info>
  <brief_title>Ramipril for the Treatment of COVID-19</brief_title>
  <acronym>RAMIC</acronym>
  <official_title>A Randomized, Double-blind, Placebo-Controlled Trial to Evaluate the Efficacy of Ramipril to Prevent ICU Admission, Need for Mechanical Ventilation or Death in Persons With COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Diego</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Diego</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study we propose to treat 560 patients with ramipril or placebo for 14 days. After an&#xD;
      initial evaluation for COVID-19 status, medical history, and symptom assessment, patients&#xD;
      will receive either 2.5 mg/day of ramipril or placebo. Patients' symptoms and study endpoints&#xD;
      will be monitored at regular intervals. After 14 days, patients will undergo a laboratory&#xD;
      assessment and an end-of-treatment follow-up visit at day 28. The primary endpoints of&#xD;
      successful therapy will be improved survival, reductions in ICU admissions, and/or reductions&#xD;
      in use of mechanical ventilator support.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 11, 2020</start_date>
  <completion_date type="Anticipated">May 2021</completion_date>
  <primary_completion_date type="Anticipated">May 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite of mortality or need for ICU admission or ventilator use</measure>
    <time_frame>14 days</time_frame>
    <description>The major primary outcome to be evaluated is improving a composite outcome of mortality or need for ICU admission or ventilator use within a 14-day window.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">560</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Ramipril 2.5mg orally daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Total 2.5 mg Ramipril per day once a day orally for 14 days&#xD;
Intervention: Ramipril</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo in the form of a capsule, taken orally for 14 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ramipril 2.5 MG Oral Capsule</intervention_name>
    <description>Include description or ramipril from protocol</description>
    <arm_group_label>Ramipril 2.5mg orally daily</arm_group_label>
    <other_name>Ramipril</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral capsule</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  Willing and able to provide written informed consent prior to performing study&#xD;
             procedures&#xD;
&#xD;
          -  Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV)-2 infection confirmed by&#xD;
             polymerase chain reaction (PCR) test ≤ 5 days before randomization OR Clinical&#xD;
             presentation consistent with COVID-19 infection (fever or cough or shortness of&#xD;
             breath) with positive IgM serology&#xD;
&#xD;
          -  Currently hospitalized or in an emergency department&#xD;
&#xD;
          -  Peripheral capillary oxygen saturation (SpO2) ≥ 93% on room air at screening&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participation in any other clinical trial of an experimental treatment for COVID-19&#xD;
             (use of hydroxycholoroquine or compassionate use of choloroquine or azithromycin is&#xD;
             allowed)&#xD;
&#xD;
          -  Concurrent treatment with other agents with actual or possible direct acting antiviral&#xD;
             activity against SARS-CoV-2 is prohibited &lt; 24 hours prior to study drug/placebo&#xD;
             dosing&#xD;
&#xD;
          -  Requiring mechanical ventilation at screening&#xD;
&#xD;
          -  Requiring ICU care at admission&#xD;
&#xD;
          -  NSAID use within 12 hours of randomization or requiring continued NSAID use during&#xD;
             this trial&#xD;
&#xD;
          -  Alanine Aminotransferase (ALT) or aspartate aminotransferase (AST) &gt; 5 X upper limit&#xD;
             of normal (ULN)&#xD;
&#xD;
          -  Estimated GFR &lt; 40 mL/min&#xD;
&#xD;
          -  History of serum creatinine ≥ 2 mg/dl in the previous 28 days&#xD;
&#xD;
          -  Systolic BP &lt; 100 mm hg or diastolic BP &lt; 65 mm hg&#xD;
&#xD;
          -  Hypersensitivity to ACEI&#xD;
&#xD;
          -  History of angioedema&#xD;
&#xD;
          -  Outpatient use of ACE inhibitor or Angiotensin II receptor blocker in the last 7 days&#xD;
&#xD;
          -  History of renal artery stenosis&#xD;
&#xD;
          -  Serum potassium ≥ 5.1 mEq/L&#xD;
&#xD;
          -  Pregnancy or breastfeeding&#xD;
&#xD;
          -  Use of aliskiren, amifostine, lithium, sacubitril within 7 days&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Len Lazaro</last_name>
    <phone>858-822-3708</phone>
    <email>llazaro@health.ucsd.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Archana Bhatt</last_name>
    <phone>858-822-2661</phone>
    <email>abhatt@health.ucsd.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of California, San Diego</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Len Lazaro</last_name>
      <phone>858-822-3708</phone>
      <email>llazaro@health.ucsd.edu</email>
    </contact>
    <contact_backup>
      <last_name>Archana Bhatt</last_name>
      <phone>858-822-2661</phone>
      <email>abhatt@health.ucsd.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.ahajournals.org/doi/abs/10.1161/CIRCRESAHA.120.317134</url>
    <description>Related Info</description>
  </link>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>April 24, 2020</study_first_submitted>
  <study_first_submitted_qc>April 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 28, 2020</study_first_posted>
  <last_update_submitted>January 19, 2021</last_update_submitted>
  <last_update_submitted_qc>January 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Diego</investigator_affiliation>
    <investigator_full_name>Rohit Loomba</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ramipril</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

